Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
Orgenesis Inc (NASDAQ:ORGS), a developer of
advanced cell therapies, has struck a deal with Columbia University
under which it will fund research to develop a cellular vaccination
product platform.
Columbia University has created a patented dual-vaccine - focusing
on pancreatic, liver and bile duct cancers - that uses whole cancer
cells as a source of antigens and the patient's own immune
cells.
Under the terms of the research pact, Orgenesis will receive an
exclusive license on the technology developed at Columbia.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
